Condition
Calcium Pyrophosphate Deposition Disease
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
Early P 1 (1)
P 2 (2)
Trial Status
Not Yet Recruiting3
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07254637Phase 2Not Yet RecruitingPrimary
Tocilizumab in Chronic Inflammatory CPPD Disease
NCT07005804Not ApplicableNot Yet RecruitingPrimary
Calcium Pyrophosphate Deposition (CPPD) Disease
NCT06768294Phase 2Not Yet RecruitingPrimary
Baricitinib in CPPD - the BAPTIST Study
NCT02243631Early Phase 1CompletedPrimary
Effect of Probenecid on Synovial Fluid ATP Levels in CPPD
Showing all 4 trials